Related Experiment Video
Updated: May 16, 2026
06:45
Rating L-DOPA-Induced Dyskinesias in the Unilaterally 6-OHDA-Lesioned Rat Model of Parkinson's Disease
Published on: October 4, 2021
Levodopa does not change cerebral vasoreactivity in Parkinson's disease
Alexandre Krainik1, Audrey Maillet, Vanessa Fleury
1Department of Neuroradiology and MRI, University Hospital of Grenoble, Grenoble, France.
Movement Disorders : Official Journal of the Movement Disorder Society
|December 15, 2012
Summary
Cerebral vasoreactivity to hypercapnia in Parkinson's disease (PD) is normal, both before and after levodopa treatment. This finding is crucial for neuroimaging studies investigating PD, ruling out altered brain blood flow as a confounding factor.
Area of Science:
- Neuroscience
- Medical Imaging
- Neurology
Background:
- Parkinson's disease (PD) is a neurodegenerative disorder affecting motor control.
- Cerebral vasoreactivity, the brain's ability to adjust blood flow, is altered in some neurological conditions.
- The impact of levodopa on cerebral vasoreactivity in PD is not well understood.
Purpose of the Study:
- To investigate cerebral vasoreactivity to hypercapnia in Parkinson's disease patients.
- To compare vasoreactivity before and after levodopa administration.
- To compare PD patients with healthy controls.
Main Methods:
- Prospective study involving 10 Parkinson's disease patients and 8 age-matched controls.
- Used 3T blood oxygenation level-dependent (BOLD) functional MRI (fMRI) with a hypercapnic stimulus (7% CO2).
- Assessed vasoreactivity OFF and ON levodopa in patients.
Main Results:
- No significant global or regional differences in BOLD signal change were found between patients OFF and ON levodopa.
- No significant differences were detected between Parkinson's disease patients and controls.
- Cerebral vasoreactivity to hypercapnia was preserved in PD patients, irrespective of levodopa status.
Conclusions:
- Cerebral vasoreactivity to hypercapnia is normal in Parkinson's disease.
- Levodopa administration does not significantly alter this vasoreactivity.
- This finding excludes altered cerebrovascular response to hypercapnia as a confounding factor in fMRI studies of PD.
Related Concept Videos
01:24Parkinson's Disease: Treatment
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
01:15Parkinson's Disease: Overview
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is to...
01:29Drugs Affecting Neurotransmitter Synthesis
Drugs affecting neurotransmitter synthesis can impact the adrenergic neuron and the synthesis of neurotransmitters. For example, α-methyltyrosine and carbidopa target specific enzymes involved in catecholamine synthesis. α-methyltyrosine inhibits the enzyme tyrosine hydroxylase, which converts tyrosine into dopamine. By blocking this enzyme, α-methyltyrosine reduces dopamine production and other catecholamines. Carbidopa, on the other hand, inhibits the enzyme dopa decarboxylase, which converts...
01:24Parkinson Disease ll: Pathophysiology
Parkinson disease (PD) is a progressive neurodegenerative disorder primarily affecting movement, with additional non-motor features. Its pathophysiology involves complex interactions among genetic susceptibility, environmental exposures, and cellular dysfunction, including dopaminergic neuron loss, protein aggregation, and mitochondrial impairment.Selective NeurodegenerationA key feature is the degeneration of dopaminergic neurons in the substantia nigra pars compacta, leading to reduced...
01:24Parkinson Disease l: Introduction
Parkinson’s disease is a chronic, progressive neurodegenerative disorder that primarily affects movement. It is characterized by motor symptoms such as resting tremors, muscle rigidity, bradykinesia (slowness of movement), and postural instability. Patients may notice hand tremors at rest, stiffness during movement, or a shuffling gait. In addition to motor features, non-motor symptoms include sleep disturbances, mood and behavioral changes, constipation, and cognitive impairment, all of which...
01:37Neural Regulation
Digestion begins with a cephalic phase that prepares the digestive system to receive food. When our brain processes visual or olfactory information about food, it triggers impulses in the cranial nerves innervating the salivary glands and stomach to prepare for food.